Showing 5571-5580 of 10820 results for "".
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- One Third Of Surveyed Women Have Removed A Photo From Social Media To Hide Their Acnehttps://practicaldermatology.com/news/one-third-of-surveyed-women-have-removed-a-photo-from-social-media-to-hide-their-acne/2458775/According to a new U.S. survey conducted by TotalBeauty and ACZONE® (dapsone) Gel 5%, acne concerns affected the social media habits of women ages 20 to 39 (n=480) when it came to photos. Of the women surveyed, two in five (n=212) admitted to editing a photo to hide their acne, while one thir
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology</
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha